Growth Metrics

Acadia Pharmaceuticals (ACAD) Revenue (2016 - 2025)

Acadia Pharmaceuticals has reported Revenue over the past 16 years, most recently at $284.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 9.39% year-over-year to $284.0 million; the TTM value through Dec 2025 reached $1.1 billion, up 11.87%, while the annual FY2025 figure was $1.1 billion, 11.87% up from the prior year.
  • Revenue for Q4 2025 was $284.0 million at Acadia Pharmaceuticals, up from $278.6 million in the prior quarter.
  • Over five years, Revenue peaked at $284.0 million in Q4 2025 and troughed at $106.6 million in Q1 2021.
  • A 5-year average of $187.9 million and a median of $185.5 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: decreased 0.68% in 2022 and later surged 73.75% in 2024.
  • Year by year, Revenue stood at $130.8 million in 2021, then rose by 4.38% to $136.5 million in 2022, then surged by 69.27% to $231.0 million in 2023, then increased by 12.36% to $259.6 million in 2024, then grew by 9.39% to $284.0 million in 2025.
  • Business Quant data shows Revenue for ACAD at $284.0 million in Q4 2025, $278.6 million in Q3 2025, and $264.6 million in Q2 2025.